C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair

Overview of attention for article published in Frontiers in Molecular Neuroscience, August 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter: 5 X users
facebook: 1 Facebook page

wikipedia: 1 Wikipedia page

Readers on

mendeley: 10 Mendeley

So far, Altmetric has seen 9 X posts from 5 X users, with an upper bound of 94,800 followers.

@FalkonWN @theworst_of_us @Radix69123161 https://t.co/zwnL697ayZ Lepší odkazem. Jde o látku, co se váže na stejný receptor, kam tretinoid. Je to slibnější léčba SCI než tretinoid samotný. Vloni ve fázi 1.

Our drug KCL-286 regulates numerous pathways in spinal cord injury for therapeutic benefit. https://t.co/jMN3ndYoXu

https://t.co/NMAmnTgiZ7 "Additionally, we identify a putative efficacy biomarker, S100B (Calcium Binding Protein B), which plasma levels correlated with axonal regeneration in nerve-injured rats."

https://t.co/NMAmnTgiZ7 "Protein expression studies showed that C286 upregulates tenascin-C, integrin-α9, and osteopontin in the injured cord."

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 5 additional X posts.